相似文献
1
First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension.
Hypertension. 2021 Dec;78(6):1859-1867. doi: 10.1161/HYPERTENSIONAHA.121.17159. Epub 2021 Oct 18.
2
Pressure-dependent, enhanced natriuretic response to low-dose, atrial natriuretic peptide infusion in essential hypertension.
J Intern Med. 1994 Dec;236(6):665-74. doi: 10.1111/j.1365-2796.1994.tb00860.x.
3
[The effects of the acute administration of atrial natriuretic peptide on the mechanisms regulating diuresis and natriuresis in the essential hypertension patient].
Ann Ital Med Int. 1991 Jul-Sep;6(3):273-83.
4
A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension.
Hypertension. 2010 Dec;56(6):1152-9. doi: 10.1161/HYPERTENSIONAHA.110.159210. Epub 2010 Oct 25.
5
MANP (M-Atrial Natriuretic Peptide) Reduces Blood Pressure and Furosemide-Induced Increase in Aldosterone in Hypertension.
Hypertension. 2022 Apr;79(4):750-760. doi: 10.1161/HYPERTENSIONAHA.121.18837. Epub 2022 Jan 20.
6
Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man.
J Clin Endocrinol Metab. 1996 Nov;81(11):3871-6. doi: 10.1210/jcem.81.11.8923831.
7
M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics.
J Am Heart Assoc. 2014 Jan 2;3(1):e000206. doi: 10.1161/JAHA.113.000206.
8
Effect of chronic infusion of atrial natriuretic factor on plasma and urinary aldosterone, plasma renin activity, blood pressure and sodium excretion in 2-K, 1-C hypertensive rats.
Clin Exp Hypertens A. 1986;8(7):1127-47. doi: 10.3109/10641968609045478.
9
Effects of chronically administered atrial natriuretic factor in aldosterone-infused hypertensive rats.
Jpn Circ J. 1988 Dec;52(12):1446-9. doi: 10.1253/jcj.52.1446.
10
Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.
Diabetes Care. 2015 Jan;38(1):132-9. doi: 10.2337/dc14-1958. Epub 2014 Nov 20.
引用本文的文献
1
Inhibiting atrial natriuretic peptide clearance reduces myocardial fibrosis and improves cardiac function in diabetic rats.
Eur Heart J Open. 2025 Mar 19;5(2):oeaf031. doi: 10.1093/ehjopen/oeaf031. eCollection 2025 Mar.
2
The Balance Between the Natriuretic Peptides and the Renin-Angiotensin-Aldosterone System in the Preservation of Ideal Cardiovascular Health.
J Clin Med. 2025 Jan 19;14(2):626. doi: 10.3390/jcm14020626.
3
Cross talk on therapeutic strategies: natriuretic peptides and inhibiting neprilysin in hypertension management.
Hypertens Res. 2025 Jan;48(1):284-300. doi: 10.1038/s41440-024-01989-w. Epub 2024 Nov 14.
4
Discovery of small molecule guanylyl cyclase B receptor positive allosteric modulators.
PNAS Nexus. 2024 Jun 6;3(6):pgae225. doi: 10.1093/pnasnexus/pgae225. eCollection 2024 Jun.
5
Porous silicon and silica carriers for delivery of peptide therapeutics.
Drug Deliv Transl Res. 2024 Dec;14(12):3549-3567. doi: 10.1007/s13346-024-01609-7. Epub 2024 May 31.
6
MANP in Hypertension With Metabolic Syndrome: Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease.
JACC Basic Transl Sci. 2023 Nov 1;9(1):18-29. doi: 10.1016/j.jacbts.2023.08.011. eCollection 2024 Jan.
7
Sex-based differences in metabolic protection by the ANP genetic variant rs5068 in the general population.
Am J Physiol Heart Circ Physiol. 2023 Sep 1;325(3):H545-H552. doi: 10.1152/ajpheart.00321.2023. Epub 2023 Jul 7.
8
zDHHC9 Regulates Cardiomyocyte Rab3a Activity and Atrial Natriuretic Peptide Secretion Through Palmitoylation of Rab3gap1.
JACC Basic Transl Sci. 2023 Feb 22;8(5):518-542. doi: 10.1016/j.jacbts.2022.11.003. eCollection 2023 May.
9
The Natriuretic Peptide System: A Single Entity, Pleiotropic Effects.
Int J Mol Sci. 2023 Jun 1;24(11):9642. doi: 10.3390/ijms24119642.
10
Natriuretic Peptides: It Is Time for Guided Therapeutic Strategies Based on Their Molecular Mechanisms.
Int J Mol Sci. 2023 Mar 7;24(6):5131. doi: 10.3390/ijms24065131.
本文引用的文献
1
Angiotensin (1-12) in Humans With Normal Blood Pressure and Primary Hypertension.
Hypertension. 2021 Mar 3;77(3):882-890. doi: 10.1161/HYPERTENSIONAHA.120.16514. Epub 2021 Jan 19.
2
Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018.
JAMA. 2020 Sep 22;324(12):1190-1200. doi: 10.1001/jama.2020.14545.
3
Cardiac natriuretic peptides.
Nat Rev Cardiol. 2020 Nov;17(11):698-717. doi: 10.1038/s41569-020-0381-0. Epub 2020 May 22.
4
Report of the National Heart, Lung, and Blood Institute Working Group on Hypertension: Barriers to Translation.
Hypertension. 2020 Apr;75(4):902-917. doi: 10.1161/HYPERTENSIONAHA.119.13887. Epub 2020 Feb 17.
5
Long-term blood pressure lowering and cGMP-activating actions of the novel ANP analog MANP.
Am J Physiol Regul Integr Comp Physiol. 2020 Apr 1;318(4):R669-R676. doi: 10.1152/ajpregu.00354.2019. Epub 2020 Feb 5.
6
Blood Pressure-Associated Genetic Variants in the Natriuretic Peptide Receptor 1 Gene Modulate Guanylate Cyclase Activity.
Circ Genom Precis Med. 2019 Aug;12(8):e002472. doi: 10.1161/CIRCGEN.119.002472. Epub 2019 Aug 20.
7
Discovery of -glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor.
J Biol Chem. 2019 Aug 23;294(34):12567-12578. doi: 10.1074/jbc.RA119.008102. Epub 2019 Jun 11.
8
Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen.
Hypertension. 2019 Jun;73(6):1249-1257. doi: 10.1161/HYPERTENSIONAHA.119.12703.
9
Molecular Implications of Natriuretic Peptides in the Protection from Hypertension and Target Organ Damage Development.
Int J Mol Sci. 2019 Feb 13;20(4):798. doi: 10.3390/ijms20040798.
10
CRRL269: a novel designer and renal-enhancing pGC-A peptide activator.
Am J Physiol Regul Integr Comp Physiol. 2018 Mar 1;314(3):R407-R414. doi: 10.1152/ajpregu.00286.2017. Epub 2017 Nov 29.
Zotero 插件